H.C. Wainwright analyst Oren Livnat raised the firm’s price target on Tarsus Pharmaceuticals to $57 from $50 and keeps a Buy rating on the shares post the Q4 report. The analyst materially lifted Xdemvy forecasts for the second quarter in as many since the launch. The firm continues to see Tarsus as undervalued on the U.S. demodex blepharitis opportunity alone.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TARS:
- Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
- Is TARS a Buy, Before Earnings?
- Tarsus Pharmaceuticals announces results from Carpo, phase 2a trial of TP-05
- Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024
- Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference
